Diabetes

Top Story

VIDEO: EMPA-REG, LEADER trial results produce ‘exciting time’ for diabetes care

July 29, 2016

NEW ORLEANS — The results of the EMPA-REG Outcome study and the LEADER trial have expanded physicians’ armamentariums to be able to decrease patients with diabetes risks for cardiovascular disease, according to Amisha Wallia, MD, MS, of Northwestern Memorial Hospital.

In the Journals

Adults with congenital heart disease at elevated risk for type 2 diabetes

July 21, 2016
Patients older than 30 years with congenital heart disease, particularly cyanotic congenital heart disease, have increased risk for developing type 2 diabetes…
In the Journals

Risk for CV outcomes, all-cause death varies by DPP-IV, TZD use

July 19, 2016
In patients with type 2 diabetes, risk for cardiovascular disease, heart failure and all-cause mortality varies by diabetes drug classes, alone and combined with…
In the JournalsPerspective

INTERSTROKE: Modifiable risk factors may explain nine of 10 acute strokes

July 18, 2016
Ten modifiable risk factors, most importantly hypertension, account for approximately 90% of acute strokes worldwide, according to the INTERSTROKE case-control study…
CME

The Patient With Severe Hypertriglyceridemia

No commercial support for this activity.

Elevated serum triglycerides are a highly prevalent yet modifiable risk factor for atherosclerotic disease and its…
More »
Video
Meeting News Coverage

VIDEO: Positive CV outcomes with SGLT2 inhibitors mark ‘an exciting time’

January 7, 2016
More »
Featured
AAHFN 2016

AAHFN 2016

Video
Meeting News Coverage

VIDEO: Daniel P. Kelly, MD, details ‘vicious cycle’ between obesity, diabetes and CVD

December 15, 2015
More »
Meeting News CoverageVideo

VIDEO: EMPA-REG, LEADER trial results produce ‘exciting time’ for diabetes care

July 29, 2016
NEW ORLEANS — The results of the EMPA-REG Outcome study and the LEADER trial have expanded physicians’ armamentariums to be able to…

In the Journals

Adults with congenital heart disease at elevated risk for type 2 diabetes

July 21, 2016
Patients older than 30 years with congenital heart disease, particularly cyanotic congenital heart disease, have increased risk for developing type 2…

In the Journals

Risk for CV outcomes, all-cause death varies by DPP-IV, TZD use

July 19, 2016
In patients with type 2 diabetes, risk for cardiovascular disease, heart failure and all-cause mortality varies by diabetes drug classes, alone and…

In the JournalsPerspective

INTERSTROKE: Modifiable risk factors may explain nine of 10 acute strokes

July 18, 2016
Ten modifiable risk factors, most importantly hypertension, account for approximately 90% of acute strokes worldwide, according to the INTERSTROKE…

Butter consumption does not increase risk of death, chronic diseases

July 15, 2016
Researchers have found that the consumption of butter does not necessarily lead to diabetes, cardiovascular disease, and mortality, compared with…

In the Journals

Arterial revascularization benefits patients with diabetes undergoing CABG

July 15, 2016
CABG with total arterial revascularization conferred better long-term mortality in patients with diabetes than conventional CABG, researchers…

In the Journals

NHANES: HbA1c increasing among adults with obesity

July 14, 2016
Adults with obesity have experienced a steady increase in mean HbA1c during the past 3 decades, which indicates a rising risk for type 2 diabetes…

In the Journals

Diabetes increases mortality risk after acute MI

July 5, 2016
Adults with diabetes have higher mortality risk after an acute MI than those without diabetes, according to data published in the Journal of

Meeting News CoverageVideo

VIDEO: Results of LEADER trial provide “robust demonstration” of cardiovascular event reduction in high-risk type 2 diabetes

July 1, 2016
NEW ORLEANS — In this video, Michael T. McDermott, MD, director of endocrinology and diabetes practice at the University of Colorado Hospital…

FDA NewsPerspective

FDA advisory committee splits on CV benefit claim for Jardiance

June 28, 2016
An FDA advisory panel on Tuesday voted 12 to 11 in favor of an expanded indication for the SGLT2 inhibitor Jardiance, supporting language in the…

More Headlines »
morganatic-roan